The secreted form of l~-amyloid precursor protein (APP) containing the Kunitz proteinase inhibitor (KPI) domain, also called protease nexin II, is internalized and degraded by cells. We show that the low density lipoprotein (LDL) receptor-related protein (LRP) is responsible for the endocytosis of secreted APP. APPs770 degradation is inhibited by an LRP antagonist called the receptor-associated protein (RAP) and by LRP antibodies and is greatly diminished in fibroblasts genetically deficient in LRP. APPs695, which lacks the KPI domain, is s poor LRP ligand. Since LRP also binds apolipoprotein E (apoE)-enriched lipoproteins and inheritance of the ~4 allele of the apoE gene is a risk factor for Alzheimer's disease (AD), these data link in a single metabolic pathway two molecules strongly implicated in the pathophysiology of AD.
Introduction
Alzheimer's disease (AD) is a late-onset neurodegenerative disorder characterized by the extracellular deposition of insoluble aggregates composed of the 40-42 amino acid A~ peptide in the brain (Glenner and Wong, 1984; Masters et al., 1985) . AI3 peptide is derived from an integral membrane protein termed I~-amyloid precursor protein (APP) (Tanzi et al., 1987; Kang et al., 1987) . The function and metabolism of APP have been the subject of intensive study owing to the fact that mutations in APP are associated with an autosomal dominant form of AD (Goate et al., 1991) and that overproduction of APP is the presumptive cause of AD in trisomy 21 (Tanzi et al., 1987; . Multiple APP isoforms can be generated by alternative splicing of mRNAs. The major isoforms in brain are APP695, APP751, and APP770 containing 695, 751, and 770 amino acids, respectively. These isoforms are transmembranous proteins having large extracellular re-*The first two authors contributed equally to this work. gions, with hydrophobic membrane-spanning domains and short cytoplasmic segments. APP is also a member of an evolutionary conserved family of proteins that include the APP-like proteins, APLP1 and APLP2 (Wasco et al., 1992 (Wasco et al., , 1993 Slunt et al., 1994) .
Secreted forms of APP are generated by proteolytic cleavages within their extracellular domain close to the transmembrane region. The extracellular regions of APP751, APP770, and APLP2 each contain a Kunitz protease inhibitor (KPI) domain encoded by an alternatively transcribed exon (Kitaguchi et al., 1988; Tanzi et al., 1988; Wasco et al,, 1993; Slunt et al., 1994) . Secreted forms of APP having the KPI domain correspond to a protease inhibitor that has been identified separately and named protease nexin II (APP/PN-2) (Van Nostrand and Cunningham, 1987; Oltersdorf et al., 1989; Van Nostrand et al., 1989) , a potent inhibitor of the blood coagulation factors IXa (Schma, ier et al., 1993) and Xla (Van Nostrand et al., 1990) . APP/PN-2 binds with high affinity to cultured fibroblasts (Johnson-Wood et al., 1994) , and APP/PN-2-proteinase complexes are internalized and degraded by cultured cells (Knauer and Cunningham, 1982; Knauer et al., 1983) , although the mechanism for this process is unknown. Recent studies have identified the low density lipoprotein (LDL) receptor-related protein (LRP) as the receptor responsible for the catabolism of another Kunitz-type inhibitor, tissue factor pathway inhibitor (TFPI) (Warshawsky et al., 1994) .
LRP is a large multiligand receptor (Krieger and Herz, 1994; Strickland et al., 1995) that is a member of the LDL receptor family, which also includes the LDL receptor (Yamamoto et al., 1984) , the very low density lipoprotein (VLDL) receptor (Takahashi et al., 1992) , and glycoprotein 330 (gp330) (Saito et al., 1994) . A 39 kDa protein, termed the receptor-associated protein (RAP) , binds to members of the LDL receptor family Kounnas et al., 1992a; Battey et al., 1994) and blocks their ligand binding capacity. LRP mediates the cellular uptake and subsequent degradation of proteinases, such as tissue-type plasminogen activator (Bu et al., 1992) and urokinase-type plasminogen activator (Kounnas et al., 1993) ; proteinase-inhibitor complexes, such as ~2-macroglobulin (~2M)-proteinase complexes Moestrup and Gliemann, 1989) ; serpin-proteinase complexes Nykjaer et al., 1992; Poller et al., 1995) ; matrix proteins, such as thrombospondin (Mikhailenko et al., 1995) ; apolipoprotein E (apoE)-enriched lipoproteins (Kowal et al., 1990; Beisiegel et al., 1989) ; hepatic lipase ; and lipoprotein lipase (Chappell et al., 1993) .
LRP is expressed in many tissues and is a major apoE receptor in the central nervous system (Rebeck et al., 1993) . Genetic data implicate inheritance of the e4 allele of apoE as a risk factor in AD Rebeck et al., 1993; Poirier et al., 1993; Saunders et al., 1993) . A possible involvement of LRP in AD is suggested ) shows an immunoblot using the APP monoclonal antibody 22Cll. In (C), the filter is stained with the monoclonal antibody AIz 90 generated to a synthetic peptide corresponding to amino acid residues 511-608 of APP. The migration position of molecular mass standards are indicated on the right in kilodaltons.
in part by the observation that LRP, as well as apoE and other LRP ligands, decorates senile plaques .
The ability of LRP to mediate the cellular catabolism of TFPI, a KPI-containing protein, led us to investigate the role of LRP in the catabolism of APPs770. In this paper we present evidence that LRP is capable of binding and We hypothesized that, like TFPI, APP, which contains a KPI domain, could be catabolized by LRP. To test this hypothesis, we purified APPs770 and APPs695 to homogeneity from cell cu Iture supernatant of cells transfected with APP770 or APP695 cDNA, respectively . Amino-terminal sequencing of purified APPs770 showed identity with residues 18-28 in APP, which corresponds to the amino-terminal sequence of the mature protein. APP,770 migrated with an apparent molecular mass of 110-120 kDa and was recognized by antibodies specific for KPI-containing APP ( Figure 1A , lane 1). Purified APP,695 had an apparent molecular mass of 100-110 kDa and was not reactive against KPI-specific antibodies ( Figure 1A , lane 2). Both APP,770 and APPs695 were detected by antibodies known to recognize both forms of APP (Figures 1B and 1C) .
Initial experiments compared the cell-mediated degradation of ~2Sl-labeled APP,770 and APP,695 in mouse embryonic fibroblasts that contain LRP with their catabolism in mouse embryonic fibroblasts that are genetically deficient in LRP (Willnow and Herz, 1994) . The iodinated proteins migrated as single bands of the expected molecular mass when analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (inset in Figure 2B ). For the cellmediated degradation experiments, increasing concentrations of ~2Sl-labeled APPs770 ( with fibroblasts for 10 h r, after which the extent of degradation was determined by measuring the amount of acid soluble radioactivity present in the medium. 12Sl-labeled APP,770 was readily degraded in a dose-dependent manner when added to LRP-expressing cells ( Figure 2A ). In contrast, fibroblasts derived from mouse embryos that are genetically deficient in LRP were unable to degrade 12% labeled APPs770 ( Figure 2B ). These data provide convincing evidence that LRP is responsible for mediating the uptake of APP,770, leading to its degradation. Unlike APP,770, 12Sl-labeled APP,695 is not efficiently degraded in LRP-expressing fibroblasts ( Figure 2C ), indicating that the KPI-containing form of APP is the preferred ligand. When experiments were conducted at high APP,770 concentrations (30 nM) and degradation measured after 18 hr, some APP,770 was degraded in a RAP-independent, but heparin-and chloroquine-dependent, manner in LRPdeficient cells (data not shown), suggesting that an additional pathway may exist for the uptake and degradation APPs770.
We also used an LRP antagonist, the 39 kDa RAP, to confirm that LRP is mediating the uptake of APP,770. RAP, a protein that was initially identified when it copurifled with LRP , binds members of the LDL receptor family and antagonizes their ligand-binding activity, preventing them from internalizing ligands (Herz et al., 1991; Williams et al., 1992; Willnow et al., 1992; Battey et al., 1994; Medh et al., 1995) . In our experiments, the degradation of ~2Sl-labeled APP,770 was completely blocked when RAP was included during the incubation period ( Figure 2A ), suggesting that LRP is likely mediating this process. It should be pointed out that while RAP is an inhibitor of the LDL receptor, VLDL receptor, and gp330, the cell lines used in these experiments do not express either the VLDL receptor or gp330. Since the LDL receptor is expressed in both cell lines (see below) and since the LRP-deficient cells degrade very little APP, the LDL receptor does not appear to contribute to the degradation of this ligand.
The catabolism of several LRP ligands, such as lipopro. tein lipase (Chappell et al., 1993) , hepatic lipase , and thrombospondin (Mikhailenko et al., 1995) , is thought to be mediated by a two-step process in which initial association of the ligand with cell surface proteoglycans may precede the subsequent LRP-mediated internalization. This initial step is inhibited by heparin, and consequently we examined the effect of heparin on APPs770 catabolism. The results reveal that inclusion of heparin during the experiment prevents the cellular-mediated degradation of APPs770 (Figure 2A ), suggesting that cell surface proteoglycans may contribute to the LRPmediated catabolism of this ligand as well.
The capacity of wild-type cells that express LRP to degrade 1251-labeled APPs770, along with the diminished ability of LRP-deficient cells to degrade this ligand, provides compelling evidence that LRP mediates the degradation of APPs770. To confirm that the LRP-deficient cells are capable of catabolizing ligands that interact with other receptors, we compared the time course of 1251-labeled LDL uptake ( Figure 3A 3C) and degraded ( Figure 3D ) in wild-type cell lines. These data demonstrate that the LRP-deficient cells are normal in their ability to endocytose ligands via other receptors, such as the LDL receptor, but are unable to endocytose LRP-dependent ligands; these data are in excellent agreement with the data of Willnow and Herz (1994) .
We next investigated the time course of cellular uptake and degradation of 1251-labeled APP,770. In these experiments, 1 nM ~2Sl-labeled APP.770 was incubated with fibroblasts for varying times at 37°C. At the indicated time, the medium was removed and the amount of ~2Sl-labeled APP,770 that had been degraded to acid soluble material was measured. The cells were washed and treated with proteinase K to release surface-bound radioligand. Radioactivity that resisted proteinase K release was considered to be intracellular. ~ZSl-labeled APP,770 was internalized by cells expressing LRP and approached a steady-state intracellular level with time ( Figure 4A ). Following a lag phase, the internalized ligand was degraded, as measured by appearance of acid soluble material secreted into the medium ( Figure 4B ). As for previous experiments, both the internalization and degradation of ~251-1abeled APP.770 was inhibited by RAP and heparin. Cells genetically deficient in LRP internalize and degrade a substantially lower amount of ~2Sl-labeled APP,770 than LRP-expressing cells ( Figures 4C and 4D) . Taken together, these data suggest that LRP mediates the cellular uptake of APP,770 that leads to its degradation. To confirm further that LRP is responsible for mediating the cellular uptake of APP,770, we used affinity-purified polyclonal antibodies against the heavy chain of LRP that are known to block the LRP-mediated internalization and degradation of ligands (Kounnas et al., 1993 Mikhailenko et al., 1995) . The results, shown in Figure 5A , demonstrate that an antibody against the ligand-binding domain of LRP greatly diminished the extent of ~2Sl-labeled APP,770 that was degraded in cells expressing LRP. A control immunoglobulin G (IgG), prepared against the cytoplasmic tail of LRP, was unable to prevent degradation of this ligand. The degradation was also blocked by the lysosomal enzyme inhibitor chloroquine, confirming that the degradation process is lysosomally mediated.
To measure the ability of LRP to bind directly to APPs770, we developed an enzyme-linked immunosorbent assay (ELISA) in which APP,770 was first captured on zinc-coated microtiter wells by virtue of its ability to bind to zinc (Bush et al., 1993) . Increasing concentrations of LRP were then added, and the amount of LRP bound to the microtiter wells was measured using a monoclonal antibody specific for LRP. High affinity binding of the antibody to APPs770-containing wells, but not to wells in which APP,770 was omitted, confirms that APP,770 was effectively captured by the zinc-coated microtiter wells ( Figure  6A ). Figure 6B demonstrates the dose response for LRP binding to APPs770 captured on microtiter wells. The apparent KD derived from nonlinear regression analysis of the data is 80 nM, which is close to the affinity (55 nM) of LRP for another proteinase inhibitor, plasminogen activator inhibitor type 1 (PAl-l) (Nykjaer et al., 1994) . LRP did not bind to microtiter wells in which APP,770 was omitted. The binding of LRP to APP,770 captured on zinc-coated microtiter plates was inhibited with RAP ( Figure 6£ ;), consistent with all other known LRP ligands and with our cellular degradation for ~251-1abeled APPs770 by LRP-expressing cells. These experiments provide direct evidence for a high affinity interaction between APP,770 and LRP.
We were interested to determine whether the formation of a proteinase complex with APP,770 enhanced the LRPmediated degradation of this ligand. Previous studies have documented that APPs770 is a potent inhibitor of factor IXa (Schmaier et al., 1993) . We compared the extent of LRP-mediated degradation of ~2Sl-labeled APP,770 and ~2Sl-labeled APP,770 complexed with factor IXa. The results, shown in Figure 7 , demonstrate that slightly more of the ~251-1abeled APP,770-factor IXa complex is degraded when compared with ~251-1abeled APP,770. We cannot rule out the possibility that APP,770 is reacting with proteinases prior to its LRP-mediated uptake and thus that complex formation of APP,770 with proteinases may be required for optimal catabolism of the complex. However, reaction with proteinases does not appear to be required for binding, since APP,770 can bind to LRP directly (see Figure 6 ). In this regard, APP,770 is similar to another proteinase inhibitor, PAl-l, that can bind to LRP in the absence of proteinases (Nykjaer et al., 1994) . It is apparent that LRP contains multiple, noninteracting ligand-binding sites Willnow et al., 1992) . To determine whether apoE could compete for the LRP-mediated degradation of ~Sl-labeled APP,770, we performed competition experiments. In these experiments, 15VLDL was first enriched with apoE3 or apoE4 to generate apoE-enriched particles that are known to bind to LRP (Kowal et al., 1989) . Cells were then incubated with ~51-1abeled APP,770 in the presence and absence of excess apoE-enriched I~VLDL, and the effect on degradation of the labeled ligand was measured. The results, shown in Figure 8 , demonstrate that I~VLDL enriched with either apoE3 or apoE4 had a slight inhibitory (approximately 20%) effect on APP,770 degradation. No difference between the two isoforms of apoE was noted. On the other hand, 15VLDL alone, which does not bind to LRP, had no effect on APP,770 catabolism. Consistent with our previous experiments, the degradation of ~Sl-labeled APP,770 is greatly diminished in cells that lack LRP (Figure 8B) . These results suggest that APP,770 and apoEenriched I~VLDL bind to distinct ligand-binding sites on LRP. The partial inhibition noted may be the result of a steric effect due to the large size of the ~VLDL particle, although other mechanisms cannot be ruled out.
Discussion
The results presented in this paper indicate that the endocytic receptor LRP is a mediator of the cellular catabolism of APP,770. This conclusion is supported by several independent lines of evidence. First, ~2Sl-labeled APPs770 is endocytosed and degraded by fibroblasts that express LRP and is greatly reduced in fibroblasts deficient in LRP. Second, the cellular degradation of ~2Sl-labeled APP,770 is blocked by RAP, an inhibitor of LRP function. Third, the cellular degradation of 12Sl-labeled APPs770 is blocked by antibodies against the LRP ligand-binding regions, but not by antibodies prepared against the LRP cytoplasmic domain. Fourth, we demonstrated a high affinity interaction between APP,770 and purified LRP. This interaction was inhibited by RAP. Consistent with the effect of heparin on other LRP ligands, heparin is an effective antagonist of the cellular catabolism of ~Sl-labeled APP,770. At this time, it is not known whether heparin directly inhibits the binding of APP,770 to LRP or whether it prevents the association of APP,770 to cell surface proteoglycans, which may assist in the LRP-mediated uptake of APP,770. In this regard, the catabolism of several LRP ligands (e.g., thrombospondin-1 [Mikhailenko et al., 1995; Godyna et al., 1995] , lipoprotein lipase [Chappell et al., 1993] , and hepatic lipase ) seem to be facilitated by interaction with cell surface proteoglycans. It is possible that APP,770, like other LRP ligands, first binds to cell surface proteoglycans and is then transferred to LRP for subsequent internalization.
Finally, our data indicate that LRP appears specific for the KPI-containing form of APP and that APP,770 complexed to proteinases is also internalized by LRP. This is consistent with the role of LRP in removing inhibited proteinases, such as a~M-proteinase complexes and complexes of serpins with their target proteinase (Nykjaer et al., 1992; Orth et al., 1992; Poller et al., 1995) . Taken together, these data provide compelling evidence that LRP is responsible for APPJ70 uptake leading to its lysosomal degradation.
Like LRP, other members of the LDL receptor, such as the VLDL receptor (Argraves et al., submitted) and gp330
A LRP-expressing cells Figure 8 . Effect of ApoE Isoforms on the Degradation of 12%Labeled APP,770 by Mouse Fibroblasts Mouse fibroblasts (2 x 105) were incubated for 18 hr at 37°C with 1251-labeled APPs770 (8.8 nM) in the absence of competitor or in the presence of either RAP (1 p.M)), 10 pg/ml apoE3-I3VLDL, 10 pg/ml apoE4-iSVLDL, or 10 pg/ml ~VLDL. The concentration of apoEenriched ~VLDL represents the ~,VLDL protein before enrichment with apoE. Panels show the amount of ~251-1abeled APP,770 degradation by mouse fibroblasts expressing LRP (A) or deficient in LRP expression (B). The data shown are means of duplicate determinations -+ SEM. The inhibition was statistically significant for both apoE3-~,VLDL and apoE4-I3VLDL and for RAP (F[4,t5] = 21.65); Fisher protected least significant difference post hoc test showed that both apoE3-~VLDL and apoE4-~,VLDL were different from ~VLDL alone (p < 0.05 for both) but not from each other. RAP was also significantly different than all other categories (p < 0.001). (Willnow et al., 1992) , also bind multiple ligands. While these receptors have overlapping ligand specificity, they exhibit a different pattern of expression. LRP is widely expressed but prominent in liver and brain and VLDL receptor in heart, muscle, adipose tissue, and brain (Sakai et al., 1994) ; gp330 is prominently expressed in specialized epithelia of the brain, lung, and kidney (Zheng et al., 1994; Kounnas et al., 1994) . Because of their similar metabolic function, these receptors may also bind to APPs770 and contribute to its clearance.
We have not yet determined whether the integral membrane form of APP can interact with LRP. APP follows at least two posttranslational processing pathways during its biosynthesis. In its constitutive secretory pathway (Esch et al., 1990; Sisodia et al., 1990) , APP is cleaved within the ectodomain to give rise to secreted APP. Alternatively, APP can be internalized from the cell surface and targeted to the lysosomal compartment, where proteolytic fragments containing the AI3 peptide appear to be generated (Golde et al., 1992; Haass et al., 1992) . The ability of LRP to bind and mediate internalization of APPs770 makes it plausible that LRP can also bind the integral membrane form of APP. We hypothesize that LRP facilitates targeting of APP to lysosomal compartments and thus may promote AI3 production by mediating the internalization and lysosomal degradation of APP. If so, modulators of the expression or function of LRP may affect AI3 production.
While the precise physiological role of APP remains to be established, the collective data support an important role for this molecule in neuronal function. Secreted forms of APP have been demonstrated to have a neuroprotective effect (Mattson et al., 1993) . APP mRNA levels are elevated following neuronal injury (Abe et at., 1991) , and KPIcontaining forms are elevated during aging . Protein levels of KPI-containing soluble APP forms may also be increased relative to non-KPI-containing forms in AD brains (R. D. M., T. Lynch, A. I. B., S. Whyte, A. Henry, S. Portbuly, G. Maltarp, T. H. Small, K. Beyreuther, and C. L. Masters, unpublished data) . APP has also been suggested to play a role in promotion of neurite outgrowth (Breen et al., 1991; Breen, 1992) and involves both the KPI domain and other portions of the APP ectodomain (Jin et al., 1994; Quiet al., 1995) . Together, these data support an important role for APP in neurite outgrowth and response to injury.
ApoE, like APP, also appears to play an important role in neuronal function and has been demonstrated to promote neurite outgrowth (Nathan et al., 1994 ) via what appears to be an LRP-mediated mechanism (Mahley, 1995) . ApoE is also increased following neural damage (Poirier et al., 1993; Mahley, 1988) . It is our hypothesis that both apoE and APP bind and target molecules for LRP-mediated uptake in normal neuronal function and after neuronal injury.
In the brain, LRP is present on neurons and reactive, but not resting astrocytes (Rebeck et al., 1993) . Interestingly, LRP, APP, APLP1, and APLP2 are all concentrated in synaptic fractions prepared from human brain (T. W. Kim, M. DiFiglia, W. Wasco, G. W. Rebeck, B. T. H., D. K. S., and R. E. T., unpublished data). Thus, LRP is localized at appropriate anatomical sites, which suggests a role in the critical balance of proteinase and proteinase inhibitor production and turnover required for synaptic integrity. Disruption of this regulation could contribute to the synaptic degeneration in AD.
With the identification of APP,770 as a novel LRP ligand, it is now evident that LRP serves as a receptor for two molecules, APP and apoE, for which specific genetic variants have been shown to be genetically linked or tightly associated with cases of familial and sporadic AD. A similar catabolic pathway for apoE and APPs770 provides a biochemical link between these two proteins. Whether this catabolic pathway contributes to the pathophysiology of AD is unknown. However, these observations may lead to insight into the molecular basis of AI~ generation and of the role of apoE in neurodegeneration in AD.
Experimental Procedures

Proteins
Human APP,770 and APP,695 were purified essentially according to the method of Moir et al. (1992) from the conditioned medium of Chinese hamster ovary cells transfected with a construct containing the human APP770 or APP695 cDNA . The purification procedure entails a sequential series of chromatography steps: Q-Sepharose, heparin-Sepharose, Mono Q, and phenyI-Superose. Secreted APP fractions were concentrated and desalted into 20 mM Tris, 150 mM NaCI (pH 7.4) on Centricon 50 protein concentrators (Amicon, Beverly, MA), and protein concentration was determined by the bicinchoninic acid protein assay (Pierce Chemical Company, Rockford, IL). Purity of APP,770 and APP,695 preparations was evaluated by staining SDS-polyacrymalide gels with silver reagents for protein and by amino-terminal sequencing. Radioiodination of secreted APP preparations was performed using Na[12Sl]iodine (Amersham Corporation, Arlington Heights, IL) and iodogen reagent (Pierce Chemical Company, Rockford, IL) to obtain specific activities ranging from 10 to 20 p.Ci/pg protein. Following radiolabeling, unincorporated iodine was separated from 1251-labeled proteins on a Sephadex G25 PD10 column (Pharmacia Biotech, Piscataway, N J) equilibrated with 1% BSA, 50 mM Tris, 150 mM NaCI (pH 8.0) (-IBS). The integrity of the radiolabeled APP,770 and APP,695 was evaluated by electrophoresis on 4%-12% polyacrylamide gradient gels (Novex, San Diego, CA), followed by autoradiograpy. For all experiments described herein, ~251-labeled APP was used within 4 hr of radiolabeling. Factor IXa was purchased from Enzyme Research Laboratories (South Bend, IN). Complexes of APP,770 with factor IXa were formed by incubation of l~51-1abeled APPJ70 and factor IXa (1:0.5 molar ratio) for 1 hr at 25°C. LRP was isolated from detergent extracts of human placenta by ~2M*-Sepharose affinity chromatography as described previously . a2M * was prepared as described elsewhere . Human RAP, expressed in bacteria as a fusion protein with glutathione S-transferase (GST), was prepared free of GST as described previously . ApoE3 was provided by Dr. J. Harmony (University of Cincinnati College of Medicine, Cincinnati, OH). ApoE4 was purchased from Calbiochem (San Diego, CA). !SVLDL was provided by Dr. R. Mahley (Gladstone Institute of Cardiovascular Disease, San Francisco, CA). Complexes of apoE and I~VLDL were formed by incubation of J3VLDL and apoE (1:4 protein ratio) for 1 hr at 25°C. LDLs were provided by Dr. D. Chappell (University of Iowa College of Medicine, Iowa City, Iowa). BSA, fraction V, was purchased from Sigma Chemical Company (St. Louis, MO).
Antibodies
The mouse monoclonal antibody to the KPI domain of APP, designated 7H5, has been described previously (Hyman et al., 1992) and was provided by Dr. D. Schenk (Athena Neurosciences, South San Francisco, CA). The mouse monoclonal antibodies to APP, 2;2C11 and AIz 90, were purchased from Soehringer Mannheim (Indianapolis, IN) . The mouse monocional antibodyto the heavychain of LRP, designated 8G1, and the rabbit polyclonal antibodies to both the 515 kDa heavy chain of LRP (R777) and to a synthetic peptide from the cytoplasmic domain of the 85 kDa light chain of LRP (R704) have been described previously Kounnas et al., 1992b) . Affinity selection of LRP IgG was accomplished by LRP-Sepharose affinity chromatography. IgG was selected from R704 serum by protein G-Sepharose chromatography. Cells A normal mouse embryo fibroblast line, designated MEF, and a mouse embryo fibroblast line genetically deficient in LRP, designated PEA13, were obtained from Dr. J. Herz (University of Texas Southwestern Medical Center, Dallas, TX) and maintained as described elsewhere (Willnow and Herz, 1994) . For secreted APP uptake and degradation experiments, cells were plated at 2 x 105 cells per well and grown for 18 hr at 37°C in 50/o CO2 in 12-well dishes. Cells were incubated with 1% Nutridoma (Boehringer Manneheim, Indianapolis, IN), in 20 mM HEPES (pH 7.4), penicillin/streptomycin, 1.5°/o BSA (assay medium) for 1 hr prior to the addition of 1251-labeled APPs770 along with competitors (RAP [1 pM], antibodies [100 p.g/ml], or heparin [100 pg/ ml]). Chloroquine (0.1 mM; Sigma Chemical Company, St. Louis, MO) was added with radiolabeled ligand to inhibit its lysosomal degradation. Determination of the amount of radiolabeled APP,770 internalized or degraded was done as described previously (Kou nnas et al., 1995) . In brief, degradation was taken as radioligand in the cell culture medium that was soluble in 10% trichloroacetic acid and was corrected for noncellular-mediated degradation that occurred in parallel wells lacking cells. The amount of radioligand that was internalized by cells was defined as the amount of radioactivity that remained associated with the cell pellet following trypsin-EDTA, proteinase K (Sigma Chemical Company, St. Louis, MO) treatment.
Immunoassays
ELISAs were performed using APP~770 captured on zinc-coated plates (R. D. M., A. I. B., K. M. Rosenkronz, L° Roder, and R. E. T., unpublished data). Zinc was immobilized on the plastic surface of microtiter wells through covalently attached nitrotriacetic acid groups. The efficiency of APP,770 capture through immobilized zinc was determined to be 2-to 3-fold higher when compared with APPs770 absorption to plastic directly. For the ELISA, microtiter wells coated with zinc were incubated with APP,770 or SSA (2 p.g/ml) in for 3 hr at 37°C. Unoccupied binding sites were blocked with 3% BSA, TBS, 10 p.M ZnCI2, 2 mM MgCI2, 2 mM CaCI2 (blocking buffer) for 1 hr at 25°C. Various concentrations of LRP (0.14-300 nM) in blocking buffer containing 0.05o/O Tween 20 were incubated with coated wells for 18 hr at 4°C. For ELISAs that measured the effects of RAP on LRP binding to APP,770, wells coated with APPs770 were incubated with LRP (25 nM) in the presence of increasing concentrations of RAP (0.2-450 nM). Following the incubation, the wells were washed and incubated with the LRP monoclonal antibody 8G1 in blocking buffer containing 0.05% Tween 20 followed by goat anti-mouse IgG conjugated to peroxidase (Sigma Chemical Company, St. Louis, MO) and the chromogenic substrate 3,3',5,5'-tetramethylbenzidine (Kirkegaard and Perry Laboratories, Gaithersburg, MD). Immunoblotting was performed as described previously (Battey et al., 1994) .
